Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Dianna M. Blau is active.

Publication


Featured researches published by Dianna M. Blau.


American Journal of Pathology | 2010

2009 Pandemic Influenza A (H1N1): Pathology and Pathogenesis of 100 Fatal Cases in the United States

Wun-Ju Shieh; Dianna M. Blau; Amy M. Denison; Marlene DeLeon-Carnes; Patricia Adem; Julu Bhatnagar; John W. Sumner; Lindy Liu; Mitesh Patel; Brigid Batten; Patricia W. Greer; Tara Jones; Chalanda Smith; Jeanine Bartlett; Jeltley L. Montague; Elizabeth H. White; Dominique Rollin; Rongbao Gao; Cynthia Seales; Heather Jost; Maureen G. Metcalfe; Cynthia S. Goldsmith; Charles D. Humphrey; Ann Schmitz; Clifton P. Drew; Christopher D. Paddock; Timothy M. Uyeki; Sherif R. Zaki

In the spring of 2009, a novel influenza A (H1N1) virus emerged in North America and spread worldwide to cause the first influenza pandemic since 1968. During the first 4 months, over 500 deaths in the United States had been associated with confirmed 2009 pandemic influenza A (H1N1) [2009 H1N1] virus infection. Pathological evaluation of respiratory specimens from initial influenza-associated deaths suggested marked differences in viral tropism and tissue damage compared with seasonal influenza and prompted further investigation. Available autopsy tissue samples were obtained from 100 US deaths with laboratory-confirmed 2009 H1N1 virus infection. Demographic and clinical data of these case-patients were collected, and the tissues were evaluated by multiple laboratory methods, including histopathological evaluation, special stains, molecular and immunohistochemical assays, viral culture, and electron microscopy. The most prominent histopathological feature observed was diffuse alveolar damage in the lung in all case-patients examined. Alveolar lining cells, including type I and type II pneumocytes, were the primary infected cells. Bacterial co-infections were identified in >25% of the case-patients. Viral pneumonia and immunolocalization of viral antigen in association with diffuse alveolar damage are prominent features of infection with 2009 pandemic influenza A (H1N1) virus. Underlying medical conditions and bacterial co-infections contributed to the fatal outcome of this infection. More studies are needed to understand the multifactorial pathogenesis of this infection.


Proceedings of the National Academy of Sciences of the United States of America | 2013

Bats are a major natural reservoir for hepaciviruses and pegiviruses

Phenix-Lan Quan; Cadhla Firth; Juliette M. Conte; Simon H. Williams; Carlos Zambrana-Torrelio; Simon J. Anthony; James A. Ellison; Amy T. Gilbert; Ivan V. Kuzmin; Michael Niezgoda; Modupe Osinubi; Sergio Recuenco; Wanda Markotter; Robert F. Breiman; Lems Kalemba; Jean Malekani; Kim A. Lindblade; Melinda K. Rostal; Rafael Ojeda-Flores; Gerardo Suzán; Lora B. Davis; Dianna M. Blau; Albert B. Ogunkoya; Danilo A. Alvarez Castillo; David Moran; Sali Ngam; Dudu Akaibe; Bernard Agwanda; Thomas Briese; Jonathan H. Epstein

Although there are over 1,150 bat species worldwide, the diversity of viruses harbored by bats has only recently come into focus as a result of expanded wildlife surveillance. Such surveys are of importance in determining the potential for novel viruses to emerge in humans, and for optimal management of bats and their habitats. To enhance our knowledge of the viral diversity present in bats, we initially surveyed 415 sera from African and Central American bats. Unbiased high-throughput sequencing revealed the presence of a highly diverse group of bat-derived viruses related to hepaciviruses and pegiviruses within the family Flaviridae. Subsequent PCR screening of 1,258 bat specimens collected worldwide indicated the presence of these viruses also in North America and Asia. A total of 83 bat-derived viruses were identified, representing an infection rate of nearly 5%. Evolutionary analyses revealed that all known hepaciviruses and pegiviruses, including those previously documented in humans and other primates, fall within the phylogenetic diversity of the bat-derived viruses described here. The prevalence, unprecedented viral biodiversity, phylogenetic divergence, and worldwide distribution of the bat-derived viruses suggest that bats are a major and ancient natural reservoir for both hepaciviruses and pegiviruses and provide insights into the evolutionary history of hepatitis C virus and the human GB viruses.


Cell | 2015

Ebola Virus Epidemiology, Transmission, and Evolution during Seven Months in Sierra Leone

Daniel J. Park; Gytis Dudas; Shirlee Wohl; Augustine Goba; Shannon Whitmer; Kristian G. Andersen; Rachel Sealfon; Jason T. Ladner; Jeffrey R. Kugelman; Christian B. Matranga; Sarah M. Winnicki; James Qu; Stephen K. Gire; Adrianne Gladden-Young; Simbirie Jalloh; Dolo Nosamiefan; Nathan L. Yozwiak; Lina M. Moses; Pan-Pan Jiang; Aaron E. Lin; Stephen F. Schaffner; Brian Bird; Jonathan S. Towner; Mambu Mamoh; Michael Gbakie; Lansana Kanneh; David Kargbo; James L.B. Massally; Fatima K. Kamara; Edwin Konuwa

Summary The 2013–2015 Ebola virus disease (EVD) epidemic is caused by the Makona variant of Ebola virus (EBOV). Early in the epidemic, genome sequencing provided insights into virus evolution and transmission and offered important information for outbreak response. Here, we analyze sequences from 232 patients sampled over 7 months in Sierra Leone, along with 86 previously released genomes from earlier in the epidemic. We confirm sustained human-to-human transmission within Sierra Leone and find no evidence for import or export of EBOV across national borders after its initial introduction. Using high-depth replicate sequencing, we observe both host-to-host transmission and recurrent emergence of intrahost genetic variants. We trace the increasing impact of purifying selection in suppressing the accumulation of nonsynonymous mutations over time. Finally, we note changes in the mucin-like domain of EBOV glycoprotein that merit further investigation. These findings clarify the movement of EBOV within the region and describe viral evolution during prolonged human-to-human transmission.


Applied and Environmental Microbiology | 2006

Isolation and Identification of Rickettsia massiliae from Rhipicephalus sanguineus Ticks Collected in Arizona

Marina E. Eremeeva; Elizabeth A. Bosserman; Linda J. Demma; Maria L. Zambrano; Dianna M. Blau

ABSTRACT Twenty Rhipicephalus sanguineus ticks collected in eastern Arizona were tested by PCR assay to establish their infection rate with spotted fever group rickettsiae. With a nested PCR assay which detects a fragment of the Rickettsia genus-specific 17-kDa antigen gene (htrA), five ticks (25%) were found to contain rickettsial DNA. One rickettsial isolate was obtained from these ticks by inoculating a suspension of a triturated tick into monolayers of Vero E6 monkey kidney cells and XTC-2 clawed toad cells, and its cell culture and genotypic characteristics were determined. Fragments of the 16S rRNA, GltA, rOmpA, rOmpB, and Sca4 genes had 100%, 100%, 99%, 99%, and 99%, respectively, nucleotide similarity to Rickettsia massiliae strain Bar29, previously isolated from R. sanguineus in Catalonia, Spain (L. Beati et al., J. Clin. Microbiol. 34:2688-2694, 1996). The new isolate, AZT80, does not elicit cytotoxic effects in Vero cells and causes a persistent infection in XTC-2 cells. The AZT80 strain is susceptible to doxycycline but resistant to rifampin and erythromycin. Whether R. massiliae AZT80 is pathogenic or infectious for dogs and humans or can cause seroconversion to spotted fever group antigens in the United States is unknown.


The New England Journal of Medicine | 2013

Fungal Infections Associated with Contaminated Methylprednisolone Injections

Rachel M. Smith; Melissa K. Schaefer; Marion Kainer; Matthew Peter Wise; Jennie Finks; Joan Duwve; Elizabeth Fontaine; Alvina D. Chu; Barbara Carothers; Amy Reilly; Jay Fiedler; Andrew Wiese; Christine Feaster; Lex Gibson; Stephanie Griese; Anne Purfield; Angela A. Cleveland; Kaitlin Benedict; Julie R. Harris; Mary E. Brandt; Dianna M. Blau; John A. Jernigan; J. Todd Weber; Benjamin J. Park

BACKGROUND Fungal infections are rare complications of injections for treatment of chronic pain. In September 2012, we initiated an investigation into fungal infections associated with injections of preservative-free methylprednisolone acetate that was purchased from a single compounding pharmacy. METHODS Three lots of methylprednisolone acetate were recalled by the pharmacy; examination of unopened vials later revealed fungus. Notification of all persons potentially exposed to implicated methylprednisolone acetate was conducted by federal, state, and local public health officials and by staff at clinical facilities that administered the drug. We collected clinical data on standardized case-report forms, and we tested for the presence of fungi in isolates and specimens by examining cultures and performing polymerase-chain-reaction assays and histopathological and immunohistochemical testing. RESULTS By October 19, 2012, more than 99% of 13,534 potentially exposed persons had been contacted. As of July 1, 2013, there were 749 reported cases of infection in 20 states, with 61 deaths (8%). Laboratory evidence of Exserohilum rostratum was present in specimens from 153 case patients (20%). Additional data were available for 728 case patients (97%); 229 of these patients (31%) had meningitis with no other documented infection. Case patients had received a median of 1 injection (range, 1 to 6) of implicated methylprednisolone acetate. The median age of the patients was 64 years (range, 15 to 97), and the median incubation period (the number of days from the last injection to the date of the first diagnosis) was 47 days (range, 0 to 249); 40 patients (5%) had a stroke. CONCLUSIONS Analysis of data from a large, multistate outbreak of fungal infections showed substantial morbidity and mortality. The infections were associated with injection of a contaminated glucocorticoid medication from a single compounding pharmacy. Rapid public health actions included prompt recall of the implicated product, notification of exposed persons, and early outreach to clinicians.


Clinical Infectious Diseases | 2011

Epidemiology of 2009 Pandemic Influenza A (H1N1) Deaths in the United States, April–July 2009

Ashley Fowlkes; Paul M. Arguin; Matthew Biggerstaff; Jacqueline Gindler; Dianna M. Blau; Seema Jain; Roseline Dhara; Joe McLaughlin; Elizabeth Turnipseed; John J. Meyer; Janice K. Louie; Alan Siniscalchi; Janet J. Hamilton; Ariane Reeves; Sarah Y. Park; Deborah Richter; Matthew D. Ritchey; Noelle Cocoros; David Blythe; Susan Peters; Ruth Lynfield; Lesha Peterson; Jannifer Anderson; Zack Moore; Robin Williams; Lisa McHugh; Carmen Cruz; Christine Waters; Shannon L. Page; Christie K. McDonald

During the spring of 2009, pandemic influenza A (H1N1) virus (pH1N1) was recognized and rapidly spread worldwide. To describe the geographic distribution and patient characteristics of pH1N1-associated deaths in the United States, the Centers for Disease Control and Prevention requested information from health departments on all laboratory-confirmed pH1N1 deaths reported from 17 April through 23 July 2009. Data were collected using medical charts, medical examiner reports, and death certificates. A total of 377 pH1N1-associated deaths were identified, for a mortality rate of .12 deaths per 100,000 population. Activity was geographically localized, with the highest mortality rates in Hawaii, New York, and Utah. Seventy-six percent of deaths occurred in persons aged 18-65 years, and 9% occurred in persons aged ≥ 65 years. Underlying medical conditions were reported for 78% of deaths: chronic lung disease among adults (39%) and neurologic disease among children (54%). Overall mortality associated with pH1N1 was low; however, the majority of deaths occurred in persons aged <65 years with underlying medical conditions.


JAMA | 2013

Raccoon Rabies Virus Variant Transmission Through Solid Organ Transplantation

Neil M. Vora; Sridhar V. Basavaraju; Katherine A. Feldman; Christopher D. Paddock; Lillian A. Orciari; Steven Gitterman; Stephanie Griese; Ryan M. Wallace; Maria A. Said; Dianna M. Blau; Gennaro Selvaggi; Andres Velasco-Villa; Jana M. Ritter; Pamela A. Yager; Agnes Kresch; Mike Niezgoda; Jesse D. Blanton; Valentina Stosor; Edward M. Falta; G. Marshall Lyon; Teresa R. Zembower; Natalia Kuzmina; Prashant K. Rohatgi; Sergio Recuenco; Sherif R. Zaki; Inger K. Damon; Richard Franka; Matthew J. Kuehnert

IMPORTANCE The rabies virus causes a fatal encephalitis and can be transmitted through tissue or organ transplantation. In February 2013, a kidney recipient with no reported exposures to potentially rabid animals died from rabies 18 months after transplantation. OBJECTIVES To investigate whether organ transplantation was the source of rabies virus exposure in the kidney recipient, and to evaluate for and prevent rabies in other transplant recipients from the same donor. DESIGN Organ donor and all transplant recipient medical records were reviewed. Laboratory tests to detect rabies virus-specific binding antibodies, rabies virus neutralizing antibodies, and rabies virus antigens were conducted on available specimens, including serum, cerebrospinal fluid, and tissues from the donor and the recipients. Viral ribonucleic acid was extracted from tissues and amplified for nucleoprotein gene sequencing for phylogenetic comparisons. MAIN OUTCOMES AND MEASURES Determination of whether the donor died from undiagnosed rabies and whether other organ recipients developed rabies. RESULTS In retrospect, the donors clinical presentation (which began with vomiting and upper extremity paresthesias and progressed to fever, seizures, dysphagia, autonomic dysfunction, and brain death) was consistent with rabies. Rabies virus antigen was detected in archived autopsy brain tissue collected from the donor. The rabies viruses infecting the donor and the deceased kidney recipient were consistent with the raccoon rabies virus variant and were more than 99.9% identical across the entire N gene (1349/1350 nucleotides), thus confirming organ transplantation as the route of transmission. The 3 other organ recipients remained asymptomatic, with rabies virus neutralizing antibodies detected in their serum after completion of postexposure prophylaxis (range, 0.3-40.8 IU/mL). CONCLUSIONS AND RELEVANCE Unlike the 2 previous clusters of rabies virus transmission through solid organ transplantation, there was a long incubation period in the recipient who developed rabies, and survival of 3 other recipients without pretransplant rabies vaccination. Rabies should be considered in patients with acute progressive encephalitis of unexplained etiology, especially for potential organ donors. A standard evaluation of potential donors who meet screening criteria for infectious encephalitis should be considered, and risks and benefits for recipients of organs from these donors should be evaluated.


Journal of Virology | 2011

Pathogenesis and Transmission of Triple-Reassortant Swine H1N1 Influenza Viruses Isolated before the 2009 H1N1 Pandemic

Jessica A. Belser; Kortney M. Gustin; Taronna R. Maines; Dianna M. Blau; Sherif R. Zaki; Jacqueline M. Katz; Terrence M. Tumpey

ABSTRACT The 2009 H1N1 pandemic influenza virus represents the greatest incidence of human infection with an influenza virus of swine origin to date. Moreover, triple-reassortant swine (TRS) H1N1 viruses, which share similar host and lineage origins with 2009 H1N1 viruses, have been responsible for sporadic human cases since 2005. Similar to 2009 H1N1 viruses, TRS viruses are capable of causing severe disease in previously healthy individuals and frequently manifest with gastrointestinal symptoms; however, their ability to cause severe disease has not been extensively studied. Here, we evaluated the pathogenicity and transmissibility of two TRS viruses associated with disease in humans in the ferret model. TRS and 2009 H1N1 viruses exhibited comparable viral titers and histopathologies following virus infection and were similarly unable to transmit efficiently via respiratory droplets in the ferret model. Utilizing TRS and 2009 H1N1 viruses, we conducted extensive hematologic and blood serum analyses on infected ferrets to identify lymphohematopoietic parameters associated with mild to severe influenza virus infection. Following H1N1 or H5N1 influenza virus infection, ferrets were found to recapitulate several laboratory abnormalities previously documented with human disease, furthering the utility of the ferret model for the assessment of influenza virus pathogenicity.


American Journal of Pathology | 2013

Cytokine and Chemokine Profiles in Lung Tissues from Fatal Cases of 2009 Pandemic Influenza A (H1N1): Role of the Host Immune Response in Pathogenesis

Rongbao Gao; Julu Bhatnagar; Dianna M. Blau; Patricia W. Greer; Dominique Rollin; Amy M. Denison; Marlene DeLeon-Carnes; Wun-Ju Shieh; Suryaprakash Sambhara; Terrence M. Tumpey; Mitesh Patel; Lindy Liu; Christopher D. Paddock; Clifton P. Drew; Yuelong Shu; Jacqueline M. Katz; Sherif R. Zaki

Pathological studies on fatal cases caused by 2009 pandemic influenza H1N1 virus (2009 pH1N1) reported extensive diffuse alveolar damage and virus infection predominantly in the lung parenchyma. However, the host immune response after severe 2009 pH1N1 infection is poorly understood. Herein, we investigated viral load, the immune response, and apoptosis in lung tissues from 50 fatal cases with 2009 pH1N1 virus infection. The results suggested that 7 of the 27 cytokines/chemokines showed remarkably high expression, including IL-1 receptor antagonist protein, IL-6, tumor necrosis factor-α, IL-8, monocyte chemoattractant protein-1, macrophage inflammatory protein 1-β, and interferon-inducible protein-10 in lung tissues of 2009 pH1N1 fatal cases. Viral load, which showed the highest level on day 7 of illness onset and persisted until day 17 of illness, was positively correlated with mRNA levels of IL-1 receptor antagonist protein, monocyte chemoattractant protein-1, macrophage inflammatory protein 1-β, interferon-inducible protein-10, and regulated on activation normal T-cell expressed and secreted. Apoptosis was evident in lung tissues stained by the TUNEL assay. Decreased Fas and elevated FasL mRNA levels were present in lung tissues, and cleaved caspase-3 was frequently seen in pneumocytes, submucosal glands, and lymphoid tissues. The pathogenesis of the 2009 pH1N1 virus infection is associated with viral replication and production of proinflammatory mediators. FasL and caspase-3 are involved in the pathway of 2009 pH1N1 virus-induced apoptosis in lung tissues, and the disequilibrium between the Fas and FasL level in lung tissues could contribute to delayed clearance of the virus and subsequent pathological damages.


Vaccine | 2010

NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets.

Bin Zhou; Yan Li; Jessica A. Belser; Melissa B. Pearce; Mirco Schmolke; Anju X. Subba; Zhengli Shi; Sherif R. Zaki; Dianna M. Blau; Adolfo García-Sastre; Terrence M. Tumpey; David E. Wentworth

Although vaccines against influenza A virus are the most effective method to combat infection, it is clear that their production needs to be accelerated and their efficacy improved. We generated live attenuated human influenza A vaccines (LAIVs) by rationally engineering mutations directly into the genome of a pandemic-H1N1 virus. Two LAIVs (NS1-73 and NS1-126) were based on the success of LAIVs for animal influenza A viruses. A third candidate (NSΔ5) is a unique NS-mutant that has never been used as a LAIV. The vaccine potential of each LAIV was determined through analysis of attenuation, interferon production, immunogenicity, and their ability to protect mice and ferrets. This study demonstrates that NSΔ5 is an ideal LAIV candidate, provides important information on the effects that different NS mutations have on the pandemic-H1N1 virus and shows that LAIVs can be engineered directly from the genomes of emerging/circulating influenza A viruses.

Collaboration


Dive into the Dianna M. Blau's collaboration.

Top Co-Authors

Avatar

Sherif R. Zaki

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Christopher D. Paddock

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Julu Bhatnagar

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Wun-Ju Shieh

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Atis Muehlenbachs

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Dominique Rollin

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jana M. Ritter

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Clifton P. Drew

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Lindy Liu

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Marlene DeLeon-Carnes

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge